230 related articles for article (PubMed ID: 36958998)
1. Dose-Dependent Augmentation of Neuroplasticity-Based Auditory Learning in Schizophrenia: A Double-Blind, Placebo-Controlled, Randomized, Target Engagement Clinical Trial of the NMDA Glutamate Receptor Agonist d-serine.
Sehatpour P; Iosifescu DV; De Baun HM; Shope C; Mayer MR; Gangwisch J; Dias E; Sobeih T; Choo TH; Wall MM; Medalia A; Saperstein AM; Kegeles LS; Girgis RR; Carlson M; Kantrowitz JT
Biol Psychiatry; 2023 Jul; 94(2):164-173. PubMed ID: 36958998
[TBL] [Abstract][Full Text] [Related]
2. Augmentation of learning in schizophrenia by D-serine is related to auditory and frontally-generated biomarkers: A randomized, double-blind, placebo-controlled study.
Govani V; Shastry A; Iosifescu D; Govil P; Mayer M; Sobeih T; Choo T; Wall M; Sehatpour P; Kantrowitz J
Res Sq; 2023 May; ():. PubMed ID: 37293030
[TBL] [Abstract][Full Text] [Related]
3. Grant Report on d-Serine Augmentation of Neuroplasticity-Based Auditory Learning in Schizophrenia
de la Garrigue N; Glasser J; Sehatpour P; Iosifescu DV; Dias E; Carlson M; Shope C; Sobeih T; Choo TH; Wall MM; Kegeles LS; Gangwisch J; Mayer M; Brazis S; De Baun HM; Wolfer S; Bermudez D; Arnold M; Rette D; Meftah AM; Conant M; Lieberman JA; Kantrowitz JT
J Psychiatr Brain Sci; 2020; 5(4):. PubMed ID: 32856005
[TBL] [Abstract][Full Text] [Related]
4. Neurophysiological mechanisms of cortical plasticity impairments in schizophrenia and modulation by the NMDA receptor agonist D-serine.
Kantrowitz JT; Epstein ML; Beggel O; Rohrig S; Lehrfeld JM; Revheim N; Lehrfeld NP; Reep J; Parker E; Silipo G; Ahissar M; Javitt DC
Brain; 2016 Dec; 139(Pt 12):3281-3295. PubMed ID: 27913408
[TBL] [Abstract][Full Text] [Related]
5. Auditory System Target Engagement During Plasticity-Based Interventions in Schizophrenia: A Focus on Modulation of N-Methyl-D-Aspartate-Type Glutamate Receptor Function.
Kantrowitz JT; Swerdlow NR; Dunn W; Vinogradov S
Biol Psychiatry Cogn Neurosci Neuroimaging; 2018 Jul; 3(7):581-590. PubMed ID: 29656951
[TBL] [Abstract][Full Text] [Related]
6. Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: Correlation with symptoms.
Kantrowitz JT; Epstein ML; Lee M; Lehrfeld N; Nolan KA; Shope C; Petkova E; Silipo G; Javitt DC
Schizophr Res; 2018 Jan; 191():70-79. PubMed ID: 28318835
[TBL] [Abstract][Full Text] [Related]
7. The D-amino acid oxidase inhibitor luvadaxistat improves mismatch negativity in patients with schizophrenia in a randomized trial.
O'Donnell P; Dong C; Murthy V; Asgharnejad M; Du X; Summerfelt A; Lu H; Xu L; Wendland JR; Dunayevich E; Buhl DL; Litman R; Hetrick WP; Hong LE; Rosen LB
Neuropsychopharmacology; 2023 Jun; 48(7):1052-1059. PubMed ID: 36928351
[TBL] [Abstract][Full Text] [Related]
8. A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia.
Weiser M; Heresco-Levy U; Davidson M; Javitt DC; Werbeloff N; Gershon AA; Abramovich Y; Amital D; Doron A; Konas S; Levkovitz Y; Liba D; Teitelbaum A; Mashiach M; Zimmerman Y
J Clin Psychiatry; 2012 Jun; 73(6):e728-34. PubMed ID: 22795211
[TBL] [Abstract][Full Text] [Related]
9. Mismatch negativity as an index of target engagement for excitation/inhibition-based treatment development: a double-blind, placebo-controlled, randomized, single-dose cross-over study of the serotonin type-3 receptor antagonist CVN058.
Sehatpour P; Javitt DC; De Baun HM; Carlson M; Beloborodova A; Margolin DH; Carlton MBL; Brice NL; Kantrowitz JT
Neuropsychopharmacology; 2022 Feb; 47(3):711-718. PubMed ID: 34667294
[TBL] [Abstract][Full Text] [Related]
10. N-methyl-d-aspartate-type glutamate receptor modulators and related medications for the enhancement of auditory system plasticity in schizophrenia.
Kantrowitz JT
Schizophr Res; 2019 May; 207():70-79. PubMed ID: 29459050
[TBL] [Abstract][Full Text] [Related]
11. Single-Dose Memantine Improves Cortical Oscillatory Response Dynamics in Patients with Schizophrenia.
Light GA; Zhang W; Joshi YB; Bhakta S; Talledo JA; Swerdlow NR
Neuropsychopharmacology; 2017 Dec; 42(13):2633-2639. PubMed ID: 28425497
[TBL] [Abstract][Full Text] [Related]
12. Augmentation of learning in schizophrenia by d-serine and auditory remediation is related to auditory and frontally-generated biomarkers: A randomized, double-blind, placebo-controlled study.
Govani V; Shastry AM; Iosifescu DV; Govil P; Mayer MR; Sobeih T; Choo TH; Wall MM; Sehatpour P; Kantrowitz JT
Schizophr Res; 2023 Oct; 260():205-208. PubMed ID: 37690312
[No Abstract] [Full Text] [Related]
13. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
Lane HY; Chang YC; Liu YC; Chiu CC; Tsai GE
Arch Gen Psychiatry; 2005 Nov; 62(11):1196-204. PubMed ID: 16275807
[TBL] [Abstract][Full Text] [Related]
14. D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial.
Kantrowitz JT; Woods SW; Petkova E; Cornblatt B; Corcoran CM; Chen H; Silipo G; Javitt DC
Lancet Psychiatry; 2015 May; 2(5):403-412. PubMed ID: 26360284
[TBL] [Abstract][Full Text] [Related]
15. Effect of N-methyl-D-aspartate-receptor-enhancing agents on cognition in patients with schizophrenia: A systematic review and meta-analysis of double-blind randomised controlled trials.
Chang CH; Lane HY; Tseng PT; Chen SJ; Liu CY; Lin CH
J Psychopharmacol; 2019 Apr; 33(4):436-448. PubMed ID: 30730250
[TBL] [Abstract][Full Text] [Related]
16. Effects of Augmenting N-Methyl-D-Aspartate Receptor Signaling on Working Memory and Experience-Dependent Plasticity in Schizophrenia: An Exploratory Study Using Acute d-cycloserine.
Forsyth JK; Bachman P; Mathalon DH; Roach BJ; Ye E; Asarnow RF
Schizophr Bull; 2017 Sep; 43(5):1123-1133. PubMed ID: 28338977
[TBL] [Abstract][Full Text] [Related]
17. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor.
Lane HY; Lin CH; Green MF; Hellemann G; Huang CC; Chen PW; Tun R; Chang YC; Tsai GE
JAMA Psychiatry; 2013 Dec; 70(12):1267-75. PubMed ID: 24089054
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of
Goh KK; Wu TH; Chen CH; Lu ML
J Psychopharmacol; 2021 Mar; 35(3):236-252. PubMed ID: 33406959
[TBL] [Abstract][Full Text] [Related]
19. Neurophysiological Effects of Bitopertin in Schizophrenia.
Kantrowitz JT; Nolan KA; Epstein ML; Lehrfeld N; Shope C; Petkova E; Javitt DC
J Clin Psychopharmacol; 2017 Aug; 37(4):447-451. PubMed ID: 28590364
[TBL] [Abstract][Full Text] [Related]
20. D-alanine added to antipsychotics for the treatment of schizophrenia.
Tsai GE; Yang P; Chang YC; Chong MY
Biol Psychiatry; 2006 Feb; 59(3):230-4. PubMed ID: 16154544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
